Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Octreotide Adverse Reaction”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Not applicableStudy completedNCT05171751
What this trial is testing

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

Who this might be right for
Congenital Hyperinsulinaemic HypoglycaemiaOctreotide Adverse Reaction
Beijing Children's Hospital 50
Large-scale testing (Phase 3)Study completedNCT00075868
What this trial is testing

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Who this might be right for
Anal CancerColorectal CancerDrug/Agent Toxicity by Tissue/Organ+1 more
Radiation Therapy Oncology Group 233
Testing effectiveness (Phase 2)Study completedNCT02299089
What this trial is testing

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Who this might be right for
AcromegalyNeuroendocrine Tumors
Camurus AB 12
Testing effectiveness (Phase 2)Study completedNCT00853047
What this trial is testing

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Who this might be right for
Carcinoid Syndrome
Lexicon Pharmaceuticals 23
Testing effectiveness (Phase 2)Ended earlyNCT00884715
What this trial is testing

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Who this might be right for
Carcinoid Syndrome
Endo USA Inc., a Keenova Therapeutics Company 10
Large-scale testing (Phase 3)Ended earlyNCT00092287
What this trial is testing

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Who this might be right for
Malignant Carcinoid Syndrome
Ipsen 4
Post-approval studies (Phase 4)Ended earlyNCT04140409
What this trial is testing

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Who this might be right for
Neuroendocrine TumorsCarcinoid Syndrome
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10
Large-scale testing (Phase 3)Looking for participantsNCT07087054
What this trial is testing

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Who this might be right for
Carcinoid SyndromeCarcinoidCarcinoid Tumor+6 more
Crinetics Pharmaceuticals Inc. 141
Not applicableStudy completedNCT00789841
What this trial is testing

Gastrointestinal Motility in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumor
University of Aarhus 13
Testing effectiveness (Phase 2)Study completedNCT05361668
What this trial is testing

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Who this might be right for
Carcinoid SyndromeCarcinoidCarcinoid Tumor+6 more
Crinetics Pharmaceuticals Inc. 36
Testing effectiveness (Phase 2)Study completedNCT00088595
What this trial is testing

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Who this might be right for
Carcinoid Tumors
Novartis Pharmaceuticals 45